Moderna Inc

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
60770K107
SEDOL
BGSXTS3
CIK
0001682852
www.modernatx.com
LEI: 549300EI6OKH5K5Q2G38
©
New: Infographics X-Lab
Moderna is a Member of Themefolio
          Covid19-STX          
FIGI: BBG003PHHZT1
MRNA
Moderna Inc
GICS: 35201010 · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Moderna Inc
ISIN
US60770K1079
TICKER
MRNA
MIC
XNAS
REUTERS
MRNA.OQ
BLOOMBERG
MRNA US
F&G: 64
6.456,54 S&P · 15,78 Vola-Index · 117.348,71 BTC · 1,17022 EURUSD
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
TradingView ActivTrader MT4 MT5
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESS Newswire bereitgestellt.
Fr., 01.08.2025       Moderna
US60770K1079

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026Improves 2025 expected GAAP operating...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 01.08.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.This decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer/BioNTech's COVID-19 vaccine, Comirnaty®, which...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mi., 30.07.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individua...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mo., 28.07.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presen...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 25.07.2025       Moderna
US60770K1079

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopte...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mo., 30.06.2025       Moderna
US60770K1079

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluati...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Do., 12.06.2025       Moderna
US60770K1079

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the preve...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mi., 11.06.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event:Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ETA live webcast of this presentation will be available under "Events and Presentations" in the Investors secti...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Sa., 31.05.2025       Moderna
US60770K1079

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years wit...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mi., 28.05.2025       Moderna
US60770K1079

Phase 1/2 H5 avian flu vaccine study shows positive interim resultsCompany has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT0597...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

BARRISTA SMART * AD

P R O D U C T   S U G G E S T I O N S